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Introduction: Thrombotic microangiopathies (TMAs) are rare disorders associated
with fatal outcomes if left uncared for. However, healthcare problems in developing
countries tend to limit medical assistance to patients.
Methods: We prospectively studied an Argentine cohort of 294 consecutive patients
from2013 to2016.Patients’ subcategory classification reliedonclinical symptomsand
presence or absence of trigger events associated with TMA.
Results: Main suspected disorders were the primary TMAs known as thrombotic
thrombocytopenic purpura (TTP) (n = 72/294, 24%) and atypical haemolytic uraemic
syndrome (aHUS) (n = 94/294, 32%). In acute phase, demographic parameters for
acquired TTP (aTTP) (n = 28) and aHUS (n = 47) showed that both groups were
characterised by a young median age (37 and 25 years, respectively) and female
predominance (60% and 86%). Median of a disintegrin and metalloproteinase with a
thrombospondin type 1motif, member 13 activity was significantly lower in aTTP than
in aHUS group (1.4% vs 83%) and was associated with a more severe thrombocytope-
nia (15 × 109 vs 53 × 109/L). Creatinine (Cr) and urea (Ur) were significantly increased
in aHUS compared to aTTP subjects (Cr: 3.7 vs 0.7 mg/dL, Ur: 118 vs 33 mg/dL).
Gastrointestinal and neurological symptoms were more frequent in aHUS and aTTP,
respectively.
Conclusion: The first description of a TMA cohort in Argentina revealed similar clinical
presentations to those of other countries.
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1 INTRODUCTION
Thrombotic microangiopathies (TMAs) represent a group of rare
diseases generally characterised by microangiopathic haemolytic
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the original work is properly cited.
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anaemia (MAHA) with thrombocytopenia and organ injury of variable
severity [1]. The microvascular lesion includes arterioles and capillary
walls thickening, endothelial swelling and detachment, subendothelial
accumulation of proteins and cell debris, fibrin and platelet-rich
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F IGURE 1 Flow chart of laboratory procedure for patients with clinical suspicion of TMA
Abbreviations: ADAMTS13, a disintegrin andmetalloproteinase with a thrombospondin type 1motif, member 13; aHUS, atypical haemolytic
uraemic syndrome; aTTP, acquired thrombotic thrombocytopenic purpura; cTTP, congenital thrombotic thrombocytopenic purpura; HELLP,
haemolysis, elevated liver enzymes, low platelet count; HUS, haemolytic uraemic syndrome; Ig, immunoglobulins; MAHA, microangiopathic
haemolytic anemia; STEC-HUS, Shiga toxin-producing Escherichia coliHUS; TMA, thrombotic microangiopathy.
thrombi obstructing vessel lumina with resultant tissue ischemia [2].
The list of entities belonging to TMA is extensive, and classification
remains a challenge while some pathophysiological mechanisms asso-
ciated with the syndromes are still unclear [3]. Haemolytic uraemic
syndrome (HUS) is one of the two main TMA disorders investi-
gated together with thrombotic thrombocytopenic purpura (TTP) in
the past few decades. Although the two diseases have overlapping
clinical features, HUS and TTP are pathophysiologically distinct
entities [4]. TTP is characterised by severe acquired (aTTP) or con-
genital (cTTP) deficiency of a disintegrin and metalloproteinase with
a thrombospondin type 1 motif, member 13 (ADAMTS13). Both
forms lead to persistent ultra large von Willebrand factor multimers,
platelet activation and microvascular thrombosis [5]. The triad of
acute MAHA, thrombocytopenia and acute kidney injury defines
HUS. This syndrome is characterised by the typical form, secondary
to an infection by Shiga toxin (Stx)-producing Escherichia coli (STEC)
and the extremely rare atypical form (aHUS), caused by the dysreg-
ulation of the alternative pathway of the complement, leading to
its activation. Elucidated pathological mechanisms of aHUS involve
genetic or acquired abnormalities identified in complement com-
ponents or coagulation-related factors [6]. TMA patient cohorts
contributed to depict epidemiological and demographic background
of the disease worldwide, except in Latin America where TMA reports
are almost nonexistent. The aim of our study was to describe the
demographic, laboratory and clinical features of an Argentine cohort
of 294 consecutive patients with suspected TMA from 2013 to
2016.
2 MATERIAL AND METHODS
2.1 Study design and subject population
From January 2013 until December 2016, we prospectively collected
plasma samples of 294 consecutive patients, both adults and children,
and conducted a retrospective analysis from clinical records. Samples
were collected directly from outpatients or shipped to our institution
from various health facilities in the country. Demographic (age, sex),
clinical (diarrhoea, gastrointestinal and neurological symptoms) and
laboratory parameters (haemoglobin, haematocrit, platelets count, lac-
tic acid dehydrogenase-lactate dehydrogenase [LDH], creatinine, urea)
were recorded when available. The study was approved by the Institu-
tional Ethics Committee, and written informed consent was obtained
from all subjects.
2.2 Definition of syndromes
Patients who manifested a non-immune MAHA
(haemoglobin < 12 g/dL with schistocytes, elevated LDH), throm-
bocytopenia (<150x109/L platelets count or a decrease of 25%
from baseline) with or without organ injury of variable severity were
defined as suspected TMA (Figure 1). Some patients were identified
as TMA after performing a renal biopsy. The first step was to measure
ADAMTS13 activity. When activity was less than 10%, TTP was
confirmed [7]. This diagnostic criterion identifies almost all patients
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but it was shown that the 10% cutoff level can be problematic in
some cases where normal ADAMTS13 activity can be associated with
high levels of ADAMTS13 autoantibodies [1]. In the context of our
study and to avoid misdiagnosis, we considered a category of patients
with an indeterminate range of ADAMTS13 activity between 10%
and 30%. Presence of anti-ADAMTS13 IgG, IgA, IgM or neutralising
antibodies confirmed aTTP. In absence of antibodies, the second step
was a genetic screening of ADAMTS13 consisting in the amplification
of all exons and intron-exon boundaries by polymerase chain reaction
(PCR) followed by Sanger sequencing in order to identify variants
causing cTTP. Suspicion of HUS was raised when ADAMTS13 activity
was normal in addition to MAHA, thrombocytopenia and kidney
failure. In absence of Stx, aHUS was suspected. When a primary event
(transplant, cancer, autoimmune diseases and infectious diseases) was
associated with TMA symptoms, cases were considered as secondary
TMA. Complications during pregnancy like preeclampsia and haemoly-
sis, elevated liver enzymes, low platelet count (HELLP) syndromewere
defined as another category of TMA.
2.3 Determination of ADAMTS13 parameters
in plasma by immunoassay
Measurement of ADAMTS13 activity in human plasma was performed
using Technozym ADAMTS13 Activity ELISA (Technoclone, Vienna,
Austria). The anti-ADAMTS13 IgG antibodies assay used Technozym
ADAMTS13 Inh ELISA (Technoclone, Vienna, Austria). Patient samples
werenegativewhenvaluewasbelow12U/mL, positivewhenvaluewas
above 15 U/mL and considered borderline when value was between
12 and 15 U/mL. Patients with severe deficiency of ADAMTS13 activ-
ity but absence of IgG were tested for IgA, IgM or neutralising activity
of anti-ADAMTS13 antibodies (data not shown).
2.4 Statistical analyses
Data were processed in GraphPad Prism version 5.01. Descriptive
statisticswere expressed asmedians, ranges andproportions. Compar-
isons between groups of patients were made using Wilcoxon Mann-
Whitney U test or Fisher’s exact test for quantitative or categorical
variables, respectively.
3 RESULTS
3.1 Demographic characteristics and patient
distribution in sub-categories after ADAMTS13
laboratory testing
Within the 4-year period (2013-2016) of our study, 294 patients
were referred to our Institution for study of ADAMTS13 parame-
ters. The majority of cases were female patients (n = 202) represent-
ing almost 69% of total cohort (Figure 2). Median age of the studied
F IGURE 2 Sex and age distribution of 294 consecutive patients in
an Argentine cohort with clinical suspicion of TMA
F IGURE 3 Distribution of the Argentine patient cohort (n= 294)
in distinct confirmed or suspected diagnostic categories established
through clinical manifestations and determination of ADAMTS13
parameters
population, including both adults and children, was 31 years (from 0 to
78). Diagnosis of TTP was discarded when normal ADAMTS13 param-
eters were measured. Patient’s clinical manifestations and laboratory
were reviewed to classify them in nine sub-categories (Figure 3). We
recorded 72 of 294 (24%) and 94 of 294 (32%) patients with suspected
diagnosis of TTP and aHUS, respectively, including relapses and remis-
sions in both groups. Nineteen relatives of probands (6%) were eval-
uated from those two categories. Only three (1%) STEC-HUS cases
were registered in this cohort. Among secondary TMApatients (n=46,
16%), a large majority (n = 27, 59%) was related to post-transplant
event (kidney, n = 11; bone-marrow, n = 3 and liver, n = 1), followed
by solid or haematological tumours (n = 12), and seven patients were
diagnosed with primary autoimmune diseases, including antiphospho-
lipid syndrome, systemic lupus erythematosus, scleroderma, hepatitis
and suspected connective tissue disease. Clinical infectious diseases
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F IGURE 4 Flow chart of TTP and aHUS patients selected for data analysis
Abbreviations: AD13, ADAMTS13; aHUS, atypical haemolytic uraemic syndrome; aTTP, acquired thrombotic thrombocytopenic purpura; cTTP,
congenital thrombotic thrombocytopenic purpura; Hb, hemoglobin; Ig, immunoglobulins; LDH, lactate dehydrogenase; MAHA, microangiopathic
haemolytic anemia; PLT, platelets; TTP, thrombotic thrombocytopenic purpura.
(HIV, HCV, tuberculosis) were identified in six patients. Six other cases
were associated with various events such as pancreatitis (n = 1), uter-
ine fibroids (n = 2), mild pregnancy complication (n = 2) or a case of
premature neonate with a significant patent ductus arteriosus. Confir-
mation of TMA by renal biopsy only, with incomplete pattern of clini-
cal manifestations, was categorised as other TMA (n= 11, 4%). Twenty
women (7%), diagnosed with preeclampsia or HELLP syndrome, were
studied for ADAMTS13 parameters to discard TTP diagnosis. Finally,
eight patients could not be classified due to lack of clinical data from
the acute episode or absence of suitable blood samples for ADAMTS13
testing.
3.2 ADAMTS13 parameters analysis in TTP
versus aHUS patients
Data analysis was based on ADAMTS13 activity and clinical char-
acteristics (Figure 4). In presence of MAHA and thrombocytopenia
with unknown cause, diagnosis slanted towards suspicion of TTP or
aHUS. Diagnosis of TTPwas supported in 56 of the 72 patients initially
suspected TTP as they presented ADAMTS13 activity of less than
10%. Twelve of those 56 patients were not included in the analysis as
they were in remission or receiving treatment during blood testing,
as well as eight others for which no antibodies or genetic variants
associated with ADAMTS13 were found. Genetic and antibodies
testing confirmed cTTP and aTTP diagnosis in 10 and 26 patients,
respectively. One patient with aTTP was excluded from the analysis
because of incomplete clinical data. We included three patients pre-
sentingMAHA and thrombocytopenia in the absence of kidney failure,
with an ADAMTS13 activity of between 10% and 30% and positive
title of IgG anti-ADAMTS13 antibodies (Figure 4). Patients with
normal ADAMTS13 activity were suspected of aHUS (n = 92). Sixteen
were excluded from the analysis because they were referred during
remission or treatment, and 31 because of missing clinical data. This
selection led to the analysis of 28 and 47 patients with a confirmed
laboratory diagnosis of aTTP and with clinical diagnosis of aHUS,
respectively.
3.3 Demographic and laboratory parameters
in TTP versus aHUS patients
Medianagewashigher in aTTPpatients compared to cTTP (P= .06) and
aHUS (P< .05) subjects (Table 1). Within the cTTP group, three experi-
enced a first episode during pregnancy, five during childhood and two
were diagnosed in adulthood. Acquired TTP and aHUS cohorts were
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TABLE 1 ADAMTS13 parameters of cTTP, aTTP and aHUS







Median age in years
(minimum-maximum)
24 (0-73) 37 (4-72) 25 (0-66)
Female (%) 50 86 60
Paediatric population (<18
years old)
5 (50%) 4 (14%) 19 (40%)
ADAMTS13Activity, median%
(minimum-maximum)
2.4 (0-10) 1.4 (0-30) 83 (38-140)
ADAMTS13 IgG, median U/mL
(minimum-maximum)
4 (1-8) 69 (23-860) 3 (0-19)
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13; aHUS, atypical haemolytic
uraemic syndrome; aTTP, acquired thrombotic thrombocytopenic purpura;
cTTP, congenital thrombotic thrombocytopenic purpura.
composed of amajority of femaleswhereas sex distributionwas similar
in cTTP group. Median of ADAMTS13 activity was significantly lower
in TTP than in aHUS patients (P < .0001). The presence of IgG anti-
ADAMTS13 confirmed aTTP diagnostic (Table 1). Patients with aTTP
presented a significant (P< .0001) andmore severe thrombocytopenia
compared with aHUS (Figure 5A). Low haemoglobin and haematocrit
levels are characteristics of both TMA syndromes, and no significant
differencewas observed between aTTP and aHUS (Figures 5B and 5C).
While no significant variation in LDH levels was observed between the
two groups (Figure 5D), creatinine and urea levels were significantly
higher (P < .0001) in aHUS than in aTTP (Figures 5E and 5F). Clinical
parameters in cTTP patients recorded during first episodewere similar
to parameters observed in aTTP cohort independently of age at onset
(data not shown).
3.4 Clinical presentation of extrarenal symptoms
and supportive treatments in TTP and aHUS patients
Renal failure is part of aHUS diagnosis but extrarenal manifestations
can be commonly observed in TMA disorders. Our cohort showed that
aHUS patients were more likely to present gastrointestinal symptoms
(40%) than aTTP subjects (4%) (P< .0005) (Table 2). Both groups expe-
rienced alterations in neurological function; however it was shown
to be significantly more frequent in aTTP (57%) than in aHUS (28%)
(P < .05). Patients suffering from TMA require supportive care earlier.
Atypical HUS patients rationally presented a higher rate of dialysis
than the aTTP group (62% vs 4%, P < .0001). In contrast, corticos-
teroids seemed to be more frequently administered to patients with
aTTP diagnosis (75%) than patients with aHUS clinical manifestations
(32%), but this difference was not significant. In the first 48 hours of
the acute phase, replacement therapy was applied as frequently to
F IGURE 5 Laboratory parameters analysis in aTTP versus aHUS patients during acute phase
***P< .05, Mann-Whitney U test.
Abbreviations: aHUS, atypical haemolytic uraemic syndrome; aTTP, acquired thrombotic thrombocytopenic purpura; LDH, lactate dehydrogenase.
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TABLE 2 Clinical manifestations and received treatments in aTTP and aHUS patients during acute phase
aTTP n= 28 (%) aHUS n= 47 (%) P-value*
Presence Absence Unknown Presence Absence Unknown
Gastrointestinal symptoms 1 (4) 20 (71) 7 (25) 19 (40) 21 (45) 7 (15) <.0005
Neurological symptoms 16 (57) 9 (32) 3 (11) 13 (28) 23 (49) 11 (23) <.05
Supportive treatments
Dialysis 1 (4) 14 (50) 13 (46) 29 (62) 9 (19) 9 (19) <.0001
Corticoids 21 (75) 1 (4) 6 (21) 15 (32) 1 (2) 31 (66) ns
Transfusion (RBC, plasma or platelets) 13 (46) 1 (4) 14 (50) 26 (55) 3 (7) 18 (38) ns
Plasmapheresis 21 (75) 1 (4) 6 (21) 26 (55) 2(4) 19 (41) ns
*Fisher’s exact test.
Abbreviations: aHUS, atypical haemolytic uraemic syndrome; aTTP, acquired thrombotic thrombocytopenic purpura; ns, non significant; RBC, red blood cells.
the aTTP cohort as to aHUS individuals (Table 2). The three pregnant
women diagnosed with cTTP suffered their first episode of TMA
after at least 30 weeks’ gestation and delivered live births following
caesarean section. They were all treated with corticoids and plasma-
pheresis with good response and remained asymptomatic after the
crisis. The seven patients who experienced their first episode of cTTP
in childhood (n = 5) or adulthood (n = 2) were treated with plasma
transfusion and plasmapheresis during the acute phase. Six of them
are currently receiving plasma infusion therapy every 15-20 days.
4 DISCUSSION
TMAs are rare disorders and life-threatening entities whose diagno-
sis is challenging for physicians. Most reports on TMAs have been
published mainly in Western Europe [8–10] and in the United States
[11]. More recently, data from the Asian-Pacific region have started
to emerge, including cohort studies from Australia [12], China [13]
and Korea [14]. In Latin America, TMA research has mostly focused
on STEC-HUS, described as endemic in Argentina and Uruguay [15].
Our study described the frequency of TMA in an Argentine consecu-
tive cohort for the first time. Compared to a similar study [16], TTP
and aHUS were the most frequently suspected entities. A recent ret-
rospective research on a large consecutive cohort of TMA patients
showed that less than 10% were TTP, aHUS or STEC-HUS cases [17].
The authors concluded that divergences in TMA frequency and inci-
dence among studies are likely due to the criteria initially used for
patient selection. Compared to studies in the literature, our limited
access to complement screening for aHUSdiagnosis reduced the scope
of our results. However, we were able to confirm TTP diagnosis in 46%
of suspected cases in our Argentine cohort. From our results we esti-
mated the annual incidence of aTTP in Argentina to be seven cases,
corresponding to 0.2 cases per million people per year. Even if aTTP
is more frequent than the inherited form, it is noteworthy to mention
that prevalence of cTTP in our Argentine cohort (n = 10/39, 26%) was
higher than in the literature. This could be partially explained by the
proportion of patients excluded from the analysis (n = 20/59), twelve
of whom had been previously diagnosedwith aTTP.
Regarding demographic characteristics, both aTTP and aHUS
groups were characterised by a predominance of females, as observed
previously [18, 19]. Our subject population of suspected TMA was
young (median age 31 years), 25% being paediatric patients. In a
similar cohort size, median age was slightly higher (34 years) in
aMalaysian study (n= 243) with 30% of cases under 24 years [20]. In a
German cohort, where the population of TMA paediatric cases was
under-represented (n = 13/232, 6%), the mean age at enrolment was
53 years [21]. Our median age for adult population only was 36 years,
which supports literature demonstrating that TMA is more frequent in
young adults [1]. The median age difference observed between aTTP
and aHUS patients in our cohort reflects that the incidence of aTTP
is higher in adults than in children, while aHUS primarily affects chil-
dren and young adults. We should not discard the possibility that the
average lower age of our cohort could be the effect of a referral bias
due to inequity in accessing quality healthcare by elderly population
in Argentina. This same selection bias, in addition to the difficulties of
accessing mid or high-complexity healthcare centres for TMA diagno-
sis could have resulted in collecting and evaluating a higher percentage
of severe cases compared to other cohorts worldwide.
The commercial chromogenic assay Technozym ADAMTS13 Activ-
ity ELISA (Chr-VWF73) is one of the most popular clinical laboratory
methods for ADAMTS13 activity. However lack of standardisation in
methodologies and sources of discrepancy between them can be chal-
lenging if carried out by non-expert laboratories. Our reference cen-
tre has accumulated experience of studying TTP patients over the past
20 years [22, 23]. This expertise is important in the management of
cases that might present divergence between laboratory results and
clinicalmanifestations, as observedbyGeorge [24]. Samplesof patients
that present overlapping results and show inconsistency with clinical
manifestations are rare but may occur [25, 26]. A recent consensus
on clinical utility of assays recommends repeating ADAMTS13 test-
ing in TMA patients with an indeterminate range of 10-20% of activity
[27]. In our cohort, 10% (n = 3) of our confirmed aTTP patients pre-
sented a normal ADAMTS13 activity (between 10% and 30%). Repeat-
ing the assay using a new sample from the patients was challenging
as subjects would usually receive replacement therapy at the earliest.
Additional methods in the laboratory were then useful to support a
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diagnosis including evaluation of ultra large VWF multimers and col-
lagen binding assay. For aHUS diagnosis, no complement biomarker
alone has proved its utility, but various serological laboratory tests are
of interest if examined altogether [28]. However, the lack of resources
encountered by developing countries is limiting their capacity to man-
age rare syndromes like TMA properly, as exposed by a recent publi-
cation from India [29]. Lack of clinical or laboratory data can be a lim-
iting factor when studying TMA. In the past few years, the PLASMIC
score was validated in the literature as a useful tool to predict TTP
early [30–32]. This prognostic score as well as others was developed
with the objective of reducing the time from diagnosis to treatment
[33]. The use of a prognostic score is of great interest in Argentina
as resources for TMA diagnosis can be limited. Moreover, our results
clearly showed that the two parameters described as useful and reli-
able to predict severeADAMTS13deficiency, platelet count and serum
creatinine [34],were indeedboth statistically significantwhen compar-
ing patients from TTP and aHUS groups.
Not only is therapeutic approach of TMA still challenging due to
the lack of treatments, but also because of diagnostic uncertainty. Our
turnaround time to measure ADAMTS13 activity can be problematic
and cause delays in considering other diagnoses and/or treatments,
which can impact patient outcomes. In that context, patients with
suspected TMA might receive plasma exchange regardless of their
real need. That being said, recommendations for TMA treatment are
to initiate plasmapheresis as soon as possible [35]. Consequently,
our cohort is composed of a high rate of aHUS patients treated with
plasmapheresis (Table 2) who also received supportive care including
dialysis and blood component transfusions. Meanwhile, initial plasma
exchange in most of aTTP patients was supplemented with corti-
costeroids administration. Additionally, a B-cell depletion molecule,
rituximab, is frequently used in immune-mediated TTP as an adjunc-
tion to initial therapy or as first-line treatment [36]. Nevertheless, poor
capacity to follow-up patients prevented us from including the number
of cases treated with rituximab in our cohort. Eculizumab for aHUS
therapy [37] is not authorised by theNational Drugs, Food andMedical
Technology Administration (ANMAT) in Argentina and can only be
accessed for compassionate use. Combined with its high cost, delays
in the administration of the drug are common and may affect patient
recovery. In developing countries, improving the diagnosis timeframe
by means of early testing will be more relevant if access to new and
expensive treatments is increased, such as caplacizumab, approved by
FDA in 2019 for TTP [38].
In conclusion, our study of 294 suspected Argentine TMA patients
represents, to the best of our knowledge, the largest cohort ever
reported in Latin America. From this dataset, clinical manifestations
and determination of ADAMTS13 parameters allowed us to describe a
high frequency of primary TMA corresponding to TTP and aHUS cases.
This study provides the first report of epidemiological information
about these rare diseases in Argentina. Accumulating data and knowl-
edge about all TMA disorders aims to offer healthcare professionals
the possibility to improve management, treatment and prevention of
affected patients.
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